- Home
- JWEL vs GNPX Comparison
JWEL vs GNPX Comparison
Compare JWEL & GNPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JWEL
- GNPX
- Stock Information
- Founded
- JWEL 2012
- GNPX 2009
- Country
- JWEL China
- GNPX United States
- Employees
- JWEL N/A
- GNPX N/A
- Industry
- JWEL Other Consumer Services
- GNPX Biotechnology: Pharmaceutical Preparations
- Sector
- JWEL Consumer Discretionary
- GNPX Health Care
- Exchange
- JWEL Nasdaq
- GNPX Nasdaq
- Market Cap
- JWEL 6.0M
- GNPX 6.1M
- IPO Year
- JWEL 2021
- GNPX 2018
- Fundamental
- Price
- JWEL $2.91
- GNPX $0.51
- Analyst Decision
- JWEL
- GNPX Strong Buy
- Analyst Count
- JWEL 0
- GNPX 1
- Target Price
- JWEL N/A
- GNPX $10.00
- AVG Volume (30 Days)
- JWEL 17.0K
- GNPX 298.1K
- Earning Date
- JWEL 12-19-2024
- GNPX 03-31-2025
- Dividend Yield
- JWEL 7.34%
- GNPX N/A
- EPS Growth
- JWEL N/A
- GNPX N/A
- EPS
- JWEL N/A
- GNPX N/A
- Revenue
- JWEL $160,009,293.00
- GNPX N/A
- Revenue This Year
- JWEL N/A
- GNPX N/A
- Revenue Next Year
- JWEL N/A
- GNPX N/A
- P/E Ratio
- JWEL N/A
- GNPX N/A
- Revenue Growth
- JWEL N/A
- GNPX N/A
- 52 Week Low
- JWEL $1.00
- GNPX $0.28
- 52 Week High
- JWEL $3.71
- GNPX $6.49
- Technical
- Relative Strength Index (RSI)
- JWEL 48.97
- GNPX 31.64
- Support Level
- JWEL $2.73
- GNPX $0.60
- Resistance Level
- JWEL $3.08
- GNPX $0.65
- Average True Range (ATR)
- JWEL 0.22
- GNPX 0.06
- MACD
- JWEL -0.03
- GNPX 0.00
- Stochastic Oscillator
- JWEL 41.38
- GNPX 6.92
About JWEL Jowell Global Ltd.
Jowell Global Ltd is a cosmetics, health and nutritional supplements, and household products e-commerce platform. It operates under Online Direct Sales, Authorized Retail Store Distribution, Third-party Merchants, and Live streaming marketing sales channels. The company's major merchandise categories are Cosmetic products, Health and nutritional supplements, and Household Products.
About GNPX Genprex Inc.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.